Substantial variability in community respiratory syncytial virus season timing

Background. Respiratory syncytial virus (RSV) is the major cause of bronchiolitis and pneumonia in young children. Prevention of RSV disease in children in certain high risk groups through use of immunoglobulin preparations has been recommended by the American Academy of Pediatrics since 1998. A more precise understanding of the timing of annual RSV epidemics should assist providers in maximizing the benefit of these preventive therapies. The objective of this study was to determine whether current national RSV surveillance data could be used to define the timing of seasonal outbreaks Methods. Weekly RSV testing data from the National Respiratory and Enteric Viruses Surveillance System for the period July 1990 through June 2000 were analyzed. RSV season onset week, peak week and duration were calculated for the entire United States, Census regions and select local laboratories. Season variability was estimated by comparing calculations for individual RSV seasons to median measurements for the entire surveillance period Results. RSV seasons in the South region began significantly earlier (P < 0.05) and lasted longer (P < 0.05) than seasons for the rest of the nation. RSV seasons in the Midwest region began significantly later (P < 0.01) and were shorter (P < 0.05) than those for the rest of the nation. Local RSV seasons varied substantially by year and by laboratory. The variability between laboratories generally increased with distance between laboratories Conclusions. Onset weeks and durations of RSV seasons vary substantially by year and location. Local RSV data are needed to accurately define the onset and offset of RSV seasons and to refine timing of passive immune prophylaxis therapy recommendations.

[1]  J. Alexander,et al.  National surveillance for respiratory syncytial virus, United States, 1985-1990. , 1994, The Journal of infectious diseases.

[2]  R. Holman,et al.  Bronchiolitis-associated hospitalizations among US children, 1980-1996. , 1999, JAMA.

[3]  Update: respiratory syncytial virus activity -- United States, 1997-98 season. , 1997, MMWR. Morbidity and mortality weekly report.

[4]  L. Anderson,et al.  Circulation patterns of group A and B human respiratory syncytial virus genotypes in 5 communities in North America. , 2000, The Journal of infectious diseases.

[5]  D. Matthews,et al.  Analysis of respiratory syncytial virus strain variation in successive epidemics in one city , 1994, Journal of clinical microbiology.

[6]  L. Wright,et al.  Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV , 1998, Pediatrics.

[7]  W. P. Glezen,et al.  Risk of primary infection and reinfection with respiratory syncytial virus. , 1986, American journal of diseases of children.

[8]  J. Sinnott,et al.  Respiratory Syncytial Virus , 1988, Infection Control & Hospital Epidemiology.

[9]  Update: respiratory syncytial virus activity--United States, 1997-98 season. , 1998, MMWR. Morbidity and mortality weekly report.

[10]  H. Tsutsumi,et al.  Genetic variability of respiratory syncytial virus subgroup a strain in 15 successive epidemics in one city , 2001, Journal of medical virology.

[11]  E. Bell,et al.  A Cost-Benefit Analysis of RSV Prophylaxis in High-Risk Infants , 2001, The Annals of pharmacotherapy.

[12]  R. Chanock,et al.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection. , 1973, American journal of epidemiology.